Alvotech (NASDAQ:ALVO) Announces Earnings Results, Misses Estimates By $0.07 EPS

Alvotech (NASDAQ:ALVO) released its quarterly earnings results on Wednesday. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.07), Zacks reports. Alvotech had a net margin of 12.12% and a negative return on equity of 23.47%. Alvotech updated its FY 2025 guidance to EPS.

Alvotech Stock Performance

Shares of NASDAQ ALVO opened at $5.52 on Friday. The company has a 50 day simple moving average of $7.72 and a two-hundred day simple moving average of $8.68. Alvotech has a fifty-two week low of $4.70 and a fifty-two week high of $13.70. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of 24.00 and a beta of 0.10.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gilder Gagnon Howe & Co. LLC purchased a new stake in Alvotech during the second quarter valued at $1,782,000. Vanguard Group Inc. boosted its position in Alvotech by 2.7% in the third quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock worth $35,481,000 after purchasing an additional 114,255 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Alvotech by 218.0% during the 2nd quarter. Bank of America Corp DE now owns 16,623 shares of the company’s stock valued at $152,000 after purchasing an additional 11,395 shares during the period. Orion Porfolio Solutions LLC purchased a new stake in shares of Alvotech during the 3rd quarter valued at about $92,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Alvotech by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 36,444 shares of the company’s stock worth $352,000 after purchasing an additional 10,573 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ALVO shares. Weiss Ratings restated a “sell (e+)” rating on shares of Alvotech in a report on Wednesday, October 8th. Northland Securities set a $10.00 price objective on shares of Alvotech in a research report on Tuesday, November 4th. Zacks Research lowered shares of Alvotech from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 21st. UBS Group dropped their target price on shares of Alvotech from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, July 18th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $8.00 price target (down previously from $14.00) on shares of Alvotech in a research report on Tuesday, November 4th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Alvotech has an average rating of “Hold” and a consensus target price of $11.50.

Alvotech Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.